Alizyme licenses Colal-Pred to Norgine
This article was originally published in Scrip
Alizyme Therapeuticshas granted Norginethe exclusive rights to Colal-Pred (prednisolone sodium metasulfobenzoate), for the treatment of ulcerative colitis, in Europe, South Africa, Australia and New Zealand. Norgine will now develop and market Colal-Pred in the areas and will pay Alizyme €2 million up-front, with the possibility of milestone payments of up to €41 million. Norgine will cover all commercialisation costs and will pay double-digit royalty sales to Alizyme.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.